Kira Pharmaceuticals is a clinical-stage biotechnology company committed to pioneering novel, transformative therapies to treat complement-mediated diseases. The company leverages its LOGIC (Lupus-targeting Ortho-paratope Guided Immunomodulating Complement) drug discovery platform to design and develop highly differentiated therapeutics. Kira's leading programs aim to address significant unmet medical needs in nephrology, hematology, and ophthalmology by precisely targeting the complement system, a key component of the innate immune system.
The Cambridge headquarters serves as the central hub for global operations, including research and development leadership, clinical development strategy, corporate functions, business development, and investor relations.
Situated in Kendall Square, known as 'the most innovative square mile on the planet,' offering proximity to world-class academic institutions, research organizations, and a dense network of biotech peers and talent.
The work culture at Kira's HQ is likely dynamic, science-driven, and collaborative, fostering innovation and a fast-paced environment typical of clinical-stage biotech companies aiming to bring novel therapies to patients.
Its location in Cambridge provides Kira with unparalleled access to scientific talent, cutting-edge research, potential collaborators, and a supportive ecosystem for biopharmaceutical advancement.
Kira Pharmaceuticals maintains a global footprint with key operations in the United States (Cambridge, MA) for corporate and R&D leadership, China (Suzhou) for R&D and potential manufacturing, and clinical trial support in Australia. This strategic presence enables global research collaboration, diverse talent acquisition, and the execution of international clinical development programs for its complement-targeted therapies.
245 Main Street, Suite 500
Cambridge
MA
USA
Address: BioBay, 218 Xinghu Street, Suzhou Industrial Park, Suzhou, Jiangsu, China
Serves as a critical R&D and operational center for the Asia-Pacific region, leveraging local talent and infrastructure to advance Kira's pipeline and support clinical trials in China.
Address: Information typically not public for small operational offices; likely co-located with CROs or as a registered office.
Facilitates the execution of clinical studies in Australia and New Zealand, engaging with clinical sites and managing regional trial logistics.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Kira Pharmaceuticals' leadership includes:
Kira Pharmaceuticals has been backed by several prominent investors over the years, including:
Kira Pharmaceuticals has made significant additions to its leadership team in the past 12-18 months, strengthening its capabilities in clinical development, finance, and legal affairs as it advances its pipeline. Notably, a new COO was appointed in early 2024.
Discover the tools Kira Pharmaceuticals uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Kira Pharmaceuticals likely utilizes common corporate email formatting conventions. The most probable formats are [first_initial][last]@kirapharma.com or [first].[last]@kirapharma.com.
flast@kirapharma.com (e.g., jdoe@kirapharma.com) or first.last@kirapharma.com (e.g. jane.doe@kirapharma.com)
Format
fbeddingfield@kirapharma.com
Example
80%
Success rate
Kira Pharmaceuticals Press Release • February 20, 2024
Kira Pharmaceuticals announced the appointment of Helen M. Boudreau as Chief Operating Officer. Ms. Boudreau brings over 25 years of experience in the biopharmaceutical industry, with a strong track record in strategic planning, operations, and corporate development....more
Kira Pharmaceuticals Press Release • October 26, 2023
Kira Pharmaceuticals presented positive topline data from its Phase 2 study of KP104 in patients with IgAN and C3G. The results demonstrated clinically meaningful improvements in proteinuria and stabilization of kidney function, with a favorable safety profile....more
Kira Pharmaceuticals Press Release • July 11, 2023
Kira Pharmaceuticals announced the appointment of Robert G. Kester as Chief Financial Officer. Mr. Kester has extensive experience in financial leadership roles within the biotechnology industry....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Kira Pharmaceuticals, are just a search away.